Positive effects of intravenous zoledronic acid on bone remodeling and structure: Are different effects on osteoblast activity to other oral bisphosphonates responsible?

Journal of Bone and Mineral Research

Volumn 23, Issue 1, 2008, Pages 2-5

  Ebeling, Peter R ^a   Burr, David B ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

BONE MINERALIZATION; BONE REMODELING; BONE STRUCTURE; CELL ACTIVITY; DRUG EFFECT; EDITORIAL; HUMAN; NONHUMAN; OSSIFICATION; OSTEOBLAST; TRABECULAR BONE;

BONE AND BONES; BONE REMODELING; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MINERALS; OSTEOBLASTS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 37549071454     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.071101     Document Type: Editorial

References (29)

1. Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, Garcia-Hernandez PA, Suporonik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF 2007 The effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 23:6-16.
2. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogolaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broel J, Di MR, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Itter J, Leb G, Mallmin H, Murray T, Ortalani S, Rubinacci A, Saaf M, Samsoie G, Verbruggen L, Meunier PJ 2002 Intravenous zoledronic acid in postmenopausal women with low bone density. N Engl J Med 346:653-661.
3. Black DM, Delmas P, Eastell R, Reid IR, Boonen S, Cauley J, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Jensen TR, Krasnow J, Hue T, Sellemeyer DE, Eriksen EF, Cummings SR 2007 Once-yearly zoledronic acid for the treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1817.
4. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S 2007 Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (in press).
5. Tobias JH, Chow JWM, Chambers TJ 1993 3-amino-1-hydrozypropylidine-1- bisphosphonate (AHPrBP) suppresses not only the induction of new, but also the persistence of existing bone-forming surfaces in rat cancellous bone. Bone 14:619-623.
6. Bikle DD, Morey-Holton ER, Doty SB, Currier PA, Tanner SJ, Halloran BP 1994 Alendronate increases skeletal mass of growing rats during unloading by inhibiting resorption of calcified cartilage. J Bone Miner Res 9:1777-1787.
7. Gasser JA, Kneissel M, Thomsen JS, Mosekilde L 2000 PTH and interactions with bisphosphonates. J Musculoskel Neuron Interact 1:53-56.
8. Lafage M-H, Balena R, Battle MA, Shea M, Seedor JG, Klein H, Hayes WC, Rodan GA 1995 Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. J Clin Invest 95:2127-2133.
9. Boyce RW, Paddock CL, Gleason JR, Sletsema WK, Eriksen EF 1995 The effects of risedronate on canine cancellous bone remodeling: Three-dimensional kinetic reconstruction of the remodeling site. J Bone Miner Res 10:211-221.
10. Allen MR, Iwata K, Phipps R, Burr DB 2006 Alterations in canine vertebral bone turnover, mirodamage accumulation and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 39:872-879.
11. Nakamura M, Udagawa N, Matsuura S, Mogi M, Nakamura H, Horiuchi H, Saito N, Hiraoka BY, Kobayashi Y, Takaoka K, Ozawa H, Miyazawa H, Takahashi N 2003 Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144:5441-5449.
12. Iwata K, Li J, Follet H, Phipps RJ, Burr DB 2006 Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. Bone 29:1053-1058.
13. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt S, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC Cummings SR for the FLEX Research Group. 2006 Effects of continuing or stopping alendronate after 5 years of treatment. JAMA 296:2927-2938.
14. Stepan JJ, Burr DB, Pavo I, Sipos A, Michalska D, Li J, Fahrleitner-Pammer A, Petto H, Westmore M, Michalsky D, Sato M, Dobnig H 2007 Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 41:378-385.
15. Foldes J, Shih M-S, Parfitt AM 1990 Frequency distributions of tetracycline-based measurements: Implications for the interpretation of bone formation indices in the absence of doublelabeled surfaces. J Bone Miner Res 5:1063-1067.
16. Boivin GY, Chavassieuz PM, Santora AC, Yates J, Meunier PJ 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687-694.
17. Roschger P, Tinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K 2001 Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29:185-191.
18. Boivin GY, Meunier PJ 2002 Effects of bisphosphonates on matrix mineralization. J Musculoskelet Neuronal Interact 2:538-543.
19. Borah B, Dufresne TE, Ritman EL, Jorgensen SM, Liu S, Chmielewski PA, Phipps FJ, Zhou X, Sibonga JD, Turner RT 2006 Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: Sequential triple biopsy studies with micro-computered tomography. Bone 39:345-352.
20. Roschger P, Fratzl P, Klaushofer K, Rodan G 1997 Mineralization of cancellous bone after alendronate and sodium fluoride treatment: A quantitative backscattered electron imaging study on minipig ribs. Bone 20:393-397.
21. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Bur DB 2001 Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524-531.
22. Burr DB, Miller L, Grynpas M, Li J, Boyde A, Mashiba T, Hirano T, Johnston CC 2003 Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone 33:960-969.
23. Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD 2004 Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34:736-746.
24. Fratzl P, Roschger P, Fratzl-Zelman N, Paschalis EP, Phipps R, Klaushofer K 2007 Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume. Calcif Tissue Int 81:73-80.
25. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF 2003 Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932-1941.
26. Chapurlat RD, Arlot M, Eiurt-Pichat B, Chavassieux P, Roux JP, Portero-Muzy N, Delmas PD 2007 Microcrack frequency and bone femodeling in postmenopausal osteoporotic women on long-term bisphosphonates: A bone biopsy study. J Bone Miner Res 22:1502-1509.
27. Cramer JA, Gold DT, Silverman SL, Lewiecki EM 2007 A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023-1031.
28. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA; Alendronate Phase III Osteoporosis Treatment Study Group. 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189-1199.
29. Black DM, Scwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santoro AC, Cummings SR 2006 Effects of continuing or stopping alendronate after 5 years of treatment - the Fracture Intervention Trial extension (FLEX): A randomised trial. JAMA 296:2927-2938.